Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Logo

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

600671.SS

(1.0)
Stock Price

8,92 CNY

-10.24% ROA

-324.58% ROE

-27.69x PER

Market Cap.

923.084.820,00 CNY

445.13% DER

0% Yield

-23.66% NPM

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Stock Analysis

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (-55.76x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (-489%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 ROE

The stock's ROE indicates a negative return (-14998.97%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-25.42%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-8), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Revenue
Year Revenue Growth
1993 42.963.088
1994 56.829.000 24.4%
1995 65.868.885 13.72%
1996 74.124.543 11.14%
1997 94.501.370 21.56%
1998 129.172.944 26.84%
1999 137.764.760 6.24%
2000 94.154.364 -46.32%
2001 144.426.652 34.81%
2002 158.235.821 8.73%
2003 196.621.969 19.52%
2004 209.710.405 6.24%
2005 238.707.452 12.15%
2006 259.671.298 8.07%
2007 265.228.863 2.1%
2008 253.978.179 -4.43%
2009 245.336.892 -3.52%
2010 234.226.890 -4.74%
2011 277.265.339 15.52%
2012 229.078.895 -21.03%
2013 281.468.861 18.61%
2014 148.727.338 -89.25%
2015 94.765.832 -56.94%
2016 123.725.458 23.41%
2017 176.382.787 29.85%
2018 358.470.846 50.8%
2019 297.072.374 -20.67%
2020 206.627.323 -43.77%
2021 147.069.186 -40.5%
2022 108.906.179 -35.04%
2023 140.613.119 22.55%
2023 121.778.535 -15.47%
2024 127.252.656 4.3%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 862.770 100%
2011 852.852 -1.16%
2012 759.922 -12.23%
2013 1.689.384 55.02%
2014 135.797 -1144.05%
2015 190.494 28.71%
2016 0 0%
2017 210.154 100%
2018 7.573.158 97.23%
2019 4.778.951 -58.47%
2020 642.881 -643.36%
2021 1.332.049 51.74%
2022 1.584.081 15.91%
2023 1.766.339 10.32%
2023 482.216 -266.3%
2024 427.184 -12.88%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 4.549.803
1994 0 0%
1995 9.264.971 100%
1996 12.836.533 27.82%
1997 13.893.697 7.61%
1998 15.823.234 12.19%
1999 15.562.062 -1.68%
2000 14.741.329 -5.57%
2001 18.110.679 18.6%
2002 18.532.342 2.28%
2003 35.623.388 47.98%
2004 22.975.229 -55.05%
2005 26.322.369 12.72%
2006 24.350.568 -8.1%
2007 27.914.065 12.77%
2008 33.254.452 16.06%
2009 41.593.463 20.05%
2010 8.189.059 -407.92%
2011 11.955.761 31.51%
2012 11.738.917 -1.85%
2013 8.249.692 -42.3%
2014 8.272.810 0.28%
2015 11.272.270 26.61%
2016 10.068.864 -11.95%
2017 12.768.602 21.14%
2018 11.969.151 -6.68%
2019 12.011.782 0.35%
2020 12.244.449 1.9%
2021 11.185.451 -9.47%
2022 12.177.119 8.14%
2023 104.566.776 88.35%
2023 13.745.545 -660.73%
2024 -25.983.799 152.9%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd EBITDA
Year EBITDA Growth
1993 7.909.053
1994 56.829.000 86.08%
1995 3.174.122 -1690.38%
1996 3.779.684 16.02%
1997 6.321.814 40.21%
1998 14.548.132 56.55%
1999 17.256.068 15.69%
2000 17.982.302 4.04%
2001 20.546.461 12.48%
2002 20.343.615 -1%
2003 4.361.135 -366.48%
2004 24.450.528 82.16%
2005 23.639.841 -3.43%
2006 18.039.087 -31.05%
2007 7.608.919 -137.08%
2008 24.124.110 68.46%
2009 -32.647.664 173.89%
2010 16.265.584 300.72%
2011 53.577.569 69.64%
2012 -24.739.841 316.56%
2013 19.772.224 225.12%
2014 19.275.879 -2.57%
2015 -5.745.049 435.52%
2016 23.159.691 124.81%
2017 32.091.990 27.83%
2018 25.921.980 -23.8%
2019 12.385.526 -109.29%
2020 9.653.663 -28.3%
2021 -1.766.364 646.53%
2022 -11.605.031 84.78%
2023 -21.270.602 45.44%
2023 -6.084.407 -249.59%
2024 -35.037.307 82.63%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Gross Profit
Year Gross Profit Growth
1993 18.076.147
1994 56.829.000 68.19%
1995 15.793.633 -259.82%
1996 20.903.394 24.44%
1997 27.646.593 24.39%
1998 41.545.924 33.46%
1999 58.967.486 29.54%
2000 55.281.075 -6.67%
2001 68.520.199 19.32%
2002 70.225.241 2.43%
2003 75.794.073 7.35%
2004 80.882.444 6.29%
2005 87.856.559 7.94%
2006 79.966.372 -9.87%
2007 81.069.340 1.36%
2008 119.229.186 32.01%
2009 95.499.190 -24.85%
2010 104.911.408 8.97%
2011 109.858.545 4.5%
2012 61.129.569 -79.71%
2013 83.202.044 26.53%
2014 59.788.643 -39.16%
2015 29.773.563 -100.81%
2016 47.653.666 37.52%
2017 71.180.679 33.05%
2018 136.771.097 47.96%
2019 147.466.174 7.25%
2020 80.178.631 -83.92%
2021 45.920.589 -74.6%
2022 24.976.396 -83.86%
2023 32.443.095 23.01%
2023 26.532.153 -22.28%
2024 30.612.484 13.33%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Net Profit
Year Net Profit Growth
1993 9.959.163
1994 15.479.000 35.66%
1995 13.445.924 -15.12%
1996 20.835.901 35.47%
1997 21.103.563 1.27%
1998 22.589.897 6.58%
1999 13.861.490 -62.97%
2000 2.484.971 -457.81%
2001 3.368.234 26.22%
2002 1.958.557 -71.98%
2003 -11.665.418 116.79%
2004 6.903.399 268.98%
2005 3.671.008 -88.05%
2006 386.430 -849.98%
2007 15.120.989 97.44%
2008 4.079.518 -270.66%
2009 -52.243.401 107.81%
2010 -8.829.625 -491.68%
2011 26.439.207 133.4%
2012 -91.592.450 128.87%
2013 2.108.420 4444.13%
2014 2.713.428 22.3%
2015 -21.543.686 112.6%
2016 1.217.184 1869.96%
2017 7.179.075 83.05%
2018 -9.876.352 172.69%
2019 50.680.106 119.49%
2020 -51.549.021 198.31%
2021 -32.781.339 -57.25%
2022 -73.207.818 55.22%
2023 -16.147.831 -353.36%
2023 -38.275.148 57.81%
2024 -35.111.782 -9.01%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 -1 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Free Cashflow
Year Free Cashflow Growth
1998 -16.746.729
1999 31.560.709 153.06%
2000 -24.627.939 228.15%
2001 1.546.954 1692.03%
2002 3.896.331 60.3%
2003 -51.324.965 107.59%
2004 -7.069.218 -626.03%
2005 -3.058.025 -131.17%
2006 41.482.599 107.37%
2007 -36.294.568 214.29%
2008 4.499.855 906.57%
2009 -21.160.250 121.27%
2010 -26.127.850 19.01%
2011 -12.723.143 -105.36%
2012 -20.406.421 37.65%
2013 760.795 2782.25%
2014 -29.805.565 102.55%
2015 -14.348.696 -107.72%
2016 -23.606.463 39.22%
2017 -37.729.544 37.43%
2018 33.243.858 213.49%
2019 66.471.419 49.99%
2020 -20.231.627 428.55%
2021 -31.133.924 35.02%
2022 -22.886.726 -36.03%
2023 -1.752.255 -1206.13%
2023 -29.384.343 94.04%
2024 -27.366.647 -7.37%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Operating Cashflow
Year Operating Cashflow Growth
1998 2.356.557
1999 49.090.489 95.2%
2000 -9.668.654 607.73%
2001 10.517.537 191.93%
2002 21.800.069 51.75%
2003 -41.134.951 153%
2004 1.354.260 3137.45%
2005 8.482.675 84.03%
2006 55.387.268 84.68%
2007 47.532.665 -16.52%
2008 21.189.180 -124.33%
2009 7.583.475 -179.41%
2010 -12.599.861 160.19%
2011 -6.492.440 -94.07%
2012 -19.822.529 67.25%
2013 12.372.830 260.21%
2014 653.790 -1792.48%
2015 -1.465.966 144.6%
2016 1.606.849 191.23%
2017 24.520.319 93.45%
2018 70.706.116 65.32%
2019 161.127.708 56.12%
2020 -8.395.915 2019.12%
2021 -26.421.706 68.22%
2022 -19.370.521 -36.4%
2023 0 0%
2023 -20.428.821 100%
2024 -24.554.700 16.8%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Capital Expenditure
Year Capital Expenditure Growth
1998 19.103.286
1999 17.529.779 -8.98%
2000 14.959.285 -17.18%
2001 8.970.582 -66.76%
2002 17.903.737 49.9%
2003 10.190.013 -75.7%
2004 8.423.478 -20.97%
2005 11.540.700 27.01%
2006 13.904.669 17%
2007 83.827.233 83.41%
2008 16.689.324 -402.28%
2009 28.743.725 41.94%
2010 13.527.989 -112.48%
2011 6.230.703 -117.12%
2012 583.892 -967.1%
2013 11.612.034 94.97%
2014 30.459.355 61.88%
2015 12.882.730 -136.44%
2016 25.213.312 48.91%
2017 62.249.863 59.5%
2018 37.462.258 -66.17%
2019 94.656.288 60.42%
2020 11.835.713 -699.75%
2021 4.712.218 -151.17%
2022 3.516.205 -34.01%
2023 1.752.255 -100.67%
2023 8.955.522 80.43%
2024 2.811.947 -218.48%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Equity
Year Equity Growth
1993 86.476.580
1994 146.437.000 40.95%
1995 174.018.456 15.85%
1996 201.515.653 13.65%
1997 225.250.877 10.54%
1998 235.711.649 4.44%
1999 244.100.674 3.44%
2000 251.285.105 2.86%
2001 251.632.397 0.14%
2002 253.204.976 0.62%
2003 242.638.444 -4.35%
2004 252.359.553 3.85%
2005 239.385.244 -5.42%
2006 236.439.012 -1.25%
2007 282.928.778 16.43%
2008 240.298.316 -17.74%
2009 187.740.847 -27.99%
2010 154.135.487 -21.8%
2011 182.836.427 15.7%
2012 92.759.012 -97.11%
2013 95.262.036 2.63%
2014 85.248.281 -11.75%
2015 62.756.380 -35.84%
2016 66.183.325 5.18%
2017 96.266.048 31.25%
2018 81.623.050 -17.94%
2019 133.326.186 38.78%
2020 93.332.337 -42.85%
2021 64.558.095 -44.57%
2022 4.479.727 -1341.12%
2023 -22.361.501 120.03%
2023 55.948.460 139.97%
2024 41.134.866 -36.01%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Assets
Year Assets Growth
1993 113.498.654
1994 192.121.000 40.92%
1995 263.021.523 26.96%
1996 259.333.698 -1.42%
1997 295.689.359 12.3%
1998 323.014.942 8.46%
1999 339.777.920 4.93%
2000 405.881.106 16.29%
2001 408.745.600 0.7%
2002 373.529.789 -9.43%
2003 346.516.617 -7.8%
2004 357.853.125 3.17%
2005 372.707.940 3.99%
2006 352.474.532 -5.74%
2007 414.089.351 14.88%
2008 369.082.005 -12.19%
2009 328.272.970 -12.43%
2010 319.794.370 -2.65%
2011 357.836.385 10.63%
2012 295.924.540 -20.92%
2013 325.268.200 9.02%
2014 285.643.496 -13.87%
2015 280.382.217 -1.88%
2016 306.193.017 8.43%
2017 450.443.108 32.02%
2018 480.615.874 6.28%
2019 526.926.931 8.79%
2020 442.510.197 -19.08%
2021 402.648.614 -9.9%
2022 299.839.827 -34.29%
2023 340.442.502 11.93%
2023 346.288.556 1.69%
2024 333.148.225 -3.94%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Liabilities
Year Liabilities Growth
1993 27.022.073
1994 192.121.000 85.93%
1995 89.003.067 -115.86%
1996 57.818.043 -53.94%
1997 70.438.480 17.92%
1998 87.303.292 19.32%
1999 95.677.246 8.75%
2000 154.596.001 38.11%
2001 157.113.202 1.6%
2002 120.324.812 -30.57%
2003 103.878.172 -15.83%
2004 105.493.570 1.53%
2005 133.322.696 20.87%
2006 116.035.520 -14.9%
2007 131.160.572 11.53%
2008 128.783.688 -1.85%
2009 140.532.122 8.36%
2010 165.658.882 15.17%
2011 174.999.957 5.34%
2012 203.165.528 13.86%
2013 230.006.163 11.67%
2014 200.395.214 -14.78%
2015 217.625.835 7.92%
2016 240.009.691 9.33%
2017 354.177.059 32.23%
2018 398.992.822 11.23%
2019 393.600.743 -1.37%
2020 349.177.858 -12.72%
2021 338.090.519 -3.28%
2022 295.360.099 -14.47%
2023 362.804.002 18.59%
2023 290.340.095 -24.96%
2024 292.013.358 0.57%

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.16
Net Income per Share
-0.27
Price to Earning Ratio
-27.69x
Price To Sales Ratio
6.55x
POCF Ratio
-50.45
PFCF Ratio
-32.44
Price to Book Ratio
49.55
EV to Sales
6.63
EV Over EBITDA
-40.17
EV to Operating CashFlow
-51.06
EV to FreeCashFlow
-32.85
Earnings Yield
-0.04
FreeCashFlow Yield
-0.03
Market Cap
0,92 Bil.
Enterprise Value
0,93 Bil.
Graham Number
0.97
Graham NetNet
-1.34

Income Statement Metrics

Net Income per Share
-0.27
Income Quality
0.55
ROE
-3.25
Return On Assets
-0.1
Return On Capital Employed
-0.39
Net Income per EBT
0.98
EBT Per Ebit
0.82
Ebit per Revenue
-0.29
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0.12
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.22
Operating Profit Margin
-0.29
Pretax Profit Margin
-0.24
Net Profit Margin
-0.24

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.18
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.15
Free CashFlow per Share
-0.23
Capex to Operating CashFlow
-0.55
Capex to Revenue
0.07
Capex to Depreciation
0.65
Return on Invested Capital
-0.41
Return on Tangible Assets
-0.1
Days Sales Outstanding
107.72
Days Payables Outstanding
232.15
Days of Inventory on Hand
176.82
Receivables Turnover
3.39
Payables Turnover
1.57
Inventory Turnover
2.06
Capex per Share
0.08

Balance Sheet

Cash per Share
0,59
Book Value per Share
0,34
Tangible Book Value per Share
0.28
Shareholders Equity per Share
0.15
Interest Debt per Share
0.75
Debt to Equity
4.45
Debt to Assets
0.25
Net Debt to EBITDA
-0.5
Current Ratio
0.74
Tangible Asset Value
0,03 Bil.
Net Current Asset Value
-0,12 Bil.
Invested Capital
100271635
Working Capital
-0,06 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,04 Bil.
Average Payables
0,07 Bil.
Average Inventory
49289436.5
Debt to Market Cap
0.09

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Dividends
Year Dividends Growth
1995 0
1998 0 0%
1999 0 0%
2001 0 0%
2002 0 0%
2005 0 0%

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Profile

About Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd, together with its subsidiaries, engages in the pharmaceutical manufacturing and drug distribution businesses in China. The company produces and sells medicines and related health care products, including tablets, granules, pills, mixtures, oral liquids, syrups, eye drops, pills, soft capsules, tablets, granules, and other health foods. It is also involved in the sale of menthol and peppermint oil raw materials, Chinese medicine formulas, Chinese medicine pieces, fresh herbs, etc.; and provision of professional medical services, such as valet decoction and distribution, slicing, and powder grinding services, as well as Chinese medicine diagnosis and treatment services. In addition, the company engages in the software development, remote health management, commercial complex management, food, Internet information businesses, etc. Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd was founded in 1958 and is headquartered in Hangzhou, China.

CEO
Mr. Bo Liu
Employee
380
Address
No. 18, Shangyang Road
Hangzhou, 311300

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Executives & BODs

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Executives & BODs
# Name Age
1 Mr. Bo Liu
Vice Chairman & President
70

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Competitors